Linked Life Data

19636701

Source:http://linkedlifedata.com/resource/pubmed/id/19636701

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-5-21
pubmed:abstractText
Amplification of chromosome 11q13 is commonly seen in breast carcinomas and candidate genes from this region include CCND1 and EMSY. Here, we investigate the prognostic significance of CCND1 and EMSY amplification in a large series of breast carcinomas and in BRCA1 and BRCA2 mutation positive breast cancers. Amplification of CCND1 and EMSY was assessed by fluorescent in situ hybridization. Both CCND1 and EMSY amplifications were associated with a significantly worse outcome in ER-positive patients treated with tamoxifen only, in contrast to nonamplified tumors (P = 8.55 x 10(-4) and P = 8.35 x 10(-5), respectively). In multivariable Cox models, which included standard prognostic markers, co-amplification of CCND1 and EMSY was significantly more predictive of outcome than was amplification of either gene alone or neither gene amplified in ER-positive tamoxifen-treated patients (P = 5.47 x 10(-5)). EMSY gene amplification was a significantly less common event in BRCA2 mutation carriers as compared to BRCA1 mutation carriers (9 versus 24%, respectively). In contrast, CCND1 amplification occurred at a similar frequency in both BRCA1 and BRCA2 breast cancers (22 versus 18%, respectively). In summary, co-amplification of CCND1 and EMSY identified a poor prognostic subset of ER-positive tamoxifen-treated patients. In addition, EMSY amplification occurred at a lower frequency in BRCA2 mutation carriers providing evidence to support EMSY amplification as a somatic surrogate for BRCA2 loss in sporadic breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1573-7217
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
121
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
347-54
pubmed:dateRevised
2011-10-13
pubmed:meshHeading
pubmed-meshheading:19636701-Breast Neoplasms, pubmed-meshheading:19636701-Cyclin D1, pubmed-meshheading:19636701-Female, pubmed-meshheading:19636701-Gene Amplification, pubmed-meshheading:19636701-Genes, BRCA1, pubmed-meshheading:19636701-Genes, BRCA2, pubmed-meshheading:19636701-Humans, pubmed-meshheading:19636701-In Situ Hybridization, Fluorescence, pubmed-meshheading:19636701-Middle Aged, pubmed-meshheading:19636701-Mutation, pubmed-meshheading:19636701-Neoplasm Proteins, pubmed-meshheading:19636701-Nuclear Proteins, pubmed-meshheading:19636701-Prognosis, pubmed-meshheading:19636701-Proportional Hazards Models, pubmed-meshheading:19636701-Receptors, Estrogen, pubmed-meshheading:19636701-Repressor Proteins, pubmed-meshheading:19636701-Selective Estrogen Receptor Modulators, pubmed-meshheading:19636701-Survival Analysis, pubmed-meshheading:19636701-Tamoxifen, pubmed-meshheading:19636701-Tissue Array Analysis, pubmed-meshheading:19636701-Treatment Outcome, pubmed-meshheading:19636701-Tumor Markers, Biological
pubmed:year
2010
pubmed:articleTitle
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
pubmed:affiliation
Center for Translational and Applied Genomics, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada. lbrown5@cw.bc.ca
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't